HER3 PET scan for advanced EGFR-mutant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study uses a special PET/CT scan to measure a protein called HER3 in your tumors. The scan uses a radioactive version of the drug patritumab deruxtecan (HER3-DXd). This test may help doctors understand how much HER3 is in your cancer and decide if HER3-targeted therapy could work for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (NSCLC) with an EGFR mutation that cannot be treated with curative intent.
- You have had at least one EGFR inhibitor treatment (like osimertinib, gefitinib, or erlotinib) for your cancer.
- You have at least two tumors that are each at least 2 cm in size.
- You are willing to have a tumor biopsy (or provide a stored sample) for the study.
- You have no history of interstitial lung disease, severe lung problems, or untreated brain metastases.
- You are 18 or older, with good overall health and organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an imaging technique that uses a special tracer to attach to HER2 (a protein on some cancer cells) and make it visible on a PET/CT scan. The goal is to see if the tracer can help doctors understand where HER2 is in the body, which may guide future treatment options for advanced lung cancer.
This study tests a special PET scan agent (an antibody tracer) to help doctors see EGFR-positive cancers without needing invasive procedures. It is mainly for early testing (Phase 1/2) to understand how well it works for imaging.
This trial tests whether two different PET scans can help doctors see how well a new type of targeted therapy (called a TROP2 ADC) is working in people with a specific kind of advanced lung cancer that has stopped responding to standard pills. The goal is to find the best way to monitor treatment and potentially improve outcomes.
This trial tests a new drug called patritumab deruxtecan for people with advanced solid tumors that have an NRG1 fusion. The drug targets a protein called HER3 on cancer cells and may help shrink tumors or slow their growth.
This Phase 1/2 trial tests whether an antibody that targets HER3 (with cetuximab, and possibly docetaxel) can help treat advanced squamous cell cancers that have already been treated or cannot use standard options. It mainly looks at safety first, and also whether the treatment can shrink tumors.
This trial uses a special PET scan (HER2-PET) to see if a targeted drug (trastuzumab deruxtecan) works better for your type of metastatic breast cancer. The goal is to match the treatment to how much HER2 protein your tumors show.
Hear when a new EGFR Gene Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.